Adynxx, Inc. (ADYX)

0.0000 0.0000 (0.00%) At close: 10:31AM EDT

Adynxx, Inc.

100 Pine Street
Suite 500
San Francisco, CA 94111
United States
415-512-7740
https://www.adynxx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 6

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Richard Orr Esq., J.D.	President, CEO, Principal Financial Officer & Director	473.59k	N/A	1961
Dr. Julien Mamet Ph.D.	Founder, Chief Scientific Officer & Director	378.47k	N/A	1976
Mr. William Martin	Executive Vice President of Corporate Development & Operations	N/A	N/A	N/A
Ms. Dina Gonzalez	Principal Accounting Officer & Senior VP of Finance	N/A	N/A	N/A
Ms. Kimberley Hebert	Senior Director of Clinical Operations	N/A	N/A	N/A

Amounts are as of 31 December 2018, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Corporate governance

Adynxx, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.